Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer

Vivian Le, Lixian Zhong, Niha L. Narsipur, Elizabeth Hays, Daniel Khuong Tran, Kimberly Rosario, Leslie Wilson

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences

Social Sciences

Chemistry